Tech Company Financing Transactions
Xeris Pharmaceuticals Funding Round
Redmile Group, ASAHI Net and Bay City Capital joined a $30 million Series C funding round for Xeris Pharmaceuticals. The round closed on 5/20/2017.
Transaction Overview
Company Name
Announced On
5/20/2017
Transaction Type
Venture Equity
Amount
$30,000,000
Round
Series C
Investors
Redmile Group (Lead Investor) (Robert Faulkner)
private investors (Paul Edick)
Proceeds Purpose
The proceeds from this financing will be used to advance the phase 3 clinical development and NDA submission of Xeris' liquid stable, prefilled, single use, glucagon auto-injector for the treatment of severe hypoglycemia in patients with Type 1 diabetes.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
3208 Red River St. 300
Austin, TX 78705
USA
Austin, TX 78705
USA
Phone
Website
Email Address
Overview
Xeris is an Austin, Texas-based specialty pharmaceutical company developing patient-friendly injectables for indications in diabetes, epilepsy, and immunology.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Paul Edick
Chief Financial Officer
Barry Deutsch
Chief Operating Officer
John Shannon
Chief Scientific Officer
Steven Prestrelski
Vice President
Allison Wey
VP - General Counsel
Beth Hecht
VP - Regulatory Affairs
Ken Johnson
Browse more venture capital transactions:
Prev: 5/20/2017: Affinity venture capital transaction
Next: 5/22/2017: ABS Entertainment Payroll venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC investment data records on this site are sourced from news reports and company announcements. The information is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs